Lawrence P. Guiheen
Lawrence P. Guiheen is Principal of Guiheen and Associates LLC, a consulting group that specializes in biopharmaceuticals commercialization. Prior to this, he was President of BioPharmaceuticals for Baxter BioScience. In that role, he managed sales and marketing of plasma and recombinant biotherapeutics in North America. Guiheen had been a senior member of the Baxter BioScience management team for over 10 years, setting the global strategy for the biopharmaceutical business.
Guiheen joined Baxter Healthcare in 1978 as a field sales representative in the New York/New Jersey area with responsibility for plasma therapeutics and blood and plasma collection devices. He quickly ascended in the organization, holding positions in marketing, sales, and operations in several of Baxter's business units, including: bone marrow and stem cell collection; processing technologies used in the treatment of oncology; diabetes insulin pumps; and homecare services.
In 1995, Guiheen was promoted to Vice President of Global Marketing for the Fenwal division with worldwide responsibilities for blood, platelet and plasma collection technologies. From this position he was promoted to Vice President of Marketing for the North America Biotech business, which included the Hyland, Fenwal and Immunotherapy business units. With the Immuno acquisition by Baxter in 1997, Guiheen was then promoted to President, Hyland Immuno North America.Guiheen is currently Chairman, Global Board of Directors of the Plasma Protein Therapeutics Association (PPTA) and past member of the board of directors of California Healthcare Institute (CHI). He holds a Bachelor of Science degree in business administration from Rutgers University.